Business Standard
Friday, May 25, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Piramal to be first pvt company to process opium
Sapna Dogra Singh / New Delhi Jul 02, 2009, 02:02 IST

State processing firms unable to meet pharma industry demand

Mumbai-based Piramal Healthcare is preparing to become the first private sector company to process opium for use in pharmaceutical products.

The development, which would end the six-decade government monopoly in processing raw opium, would help domestic pharma companies to locally source opium-based products like morphine, codeine and thebaine.

At present, two state-run firms process opium but production levels are not sufficient to meet the demand of drug makers. As a result, they import opium-based products, especially codeine.

"To reduce the dependency on imported codeine, the government is planning to add more processing capacities," a senior finance ministry official said.

Codeine is one of the most sought opium products by the Indian pharmaceutical industry, to make cough syrups. And, despite having some of the largest opium fields in the world, India annually imports about 30 tonnes of codeine.

Last year, the government decided to allow private pharma companies to process opium and manufacture opium-based drugs. Two of the country's leading pharma companies, Hyderabad-based Dr Reddy's and Mumbai-based Piramal Healthcare (formerly Nicholas Piramal) were given permission to process opium to produce substances to be used in drugs.

"We are on the project and Piramal Healthcare would start the manufacturing process by 2010," said N Santhanam, executive director and chief operating officer. A technological tie-up with a US-based firm is also in place to produce opium-based drugs, he added. But refused to divulge the firm's name.

Having a technological tie-up was one of the pre-conditions. The plant would be set up at the company's existing facility at Baddi in Himachal Pradesh. The entire project would incur an investment of about Rs 70-100 crore, though the final cost is being finalised, said Santhanam.

A government official said Dr Reddy's has not yet set up a facility. When asked, the Hyderabad-based firm, in an emailed reply, said, "Dr Reddy's is not implementing the project to produce alkaloids from opium processing."

Opium is extracted from the opium poppy. Indian opium contains a range of chemical compounds such as morphine, codeine, thebaine, noscapine and papaverine, which have widespread medical and scientific uses.

India happens to be the only country in the world with a legal mandate (under the Vienna-based International Narcotics Control Bureau) to export raw opium and produce morphine through conventional processing.

The stress now is on value addition, which is why private pharma firms have been roped in, said the finance ministry official.

Currently, the Government Opium and Alkaloids Factory (GOAF), an arm of the Ministry of Finance, department of revenue, manufactures and sells opium and its alkaloids. There are two manufacturing units located at Ghazipur in Uttar Pradesh and at Neemuch in Madhya Pradesh.

These opium factories receive, store and process opium for domestic sales and export. It is also engaged in processing the opium into alkaloids of pharmaceutical grades.

Of the total production of about 600 tonnes, 120 tonnes is needed by the factories, while 500 tonnes is exported mainly to the US and Japan. Now, 100 tonnes would be given to the private company, the ministry official said. The revenue earned from 500 tonnes of opium was Rs 200 crore during the last financial year.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets end flat
- SAIL to add 5 mn tonne capacity in FY13
- NHPC FY12 net up 28% at Rs 2,772 cr
- Aarti Industries Q4 up nearly 27% at Rs 28.24 crore
- BPCL posts four-fold jump in Q4 net at Rs 3,963 cr
  Read Business news in 
- Journey on, We are by Your Side. Click here to know more
- 2 Lac Apartments, 1 Lac House / Plots. Click here
- Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol.
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Leader in Passenger Car & Automobile Tyres. Click here
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- Learn How One City is Running on FOOD SCRAPS.
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- 36 Lakhs can get you a pool of Luxuries. Click here
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- RBI cracks down on exporters, banks Rs sees sharp rebound
- Petrol price rise offers FDI hope to retail chains
- No oil price review before June 1, two states cut tax
- Bharti Airtel acquires 49% in Qualcomm India for Rs 907 cr
- US sets more duties on India steel pipe
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us